[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477051":3},{"organization":4,"outcomesModule":7,"designInfo":7,"detailedDescription":8,"studyPopulation":7,"armGroups":7,"interventions":9,"overallOfficials":7,"centralContacts":16,"locations":22,"responsibleParty":37,"collaborators":7,"id":39,"slug":7,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":7,"acronym":7,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":7,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":53,"locationsCount":54},{"fullName":5,"class":6},"Matrix Biomed, Inc.","INDUSTRY",null,"The objective is to provide terminally diagnosed patients assigned to palliative care and palliative chemotherapy a last line treatment with Tempol. In vivo studies have shown Tempol to work synergistically with a number of chemotherapy agents increasing treatment response and reducing chemoresistance. Additionally, Tempol has been shown to provide protection to non-cancerous cells allowing for increased chemotherapy dosing by reducing side effects. Tempol inhibits HIF-1\u002FVEGF among others in cancerous cells while upregulating GSH\u002FNrF2 among others in non-cancerous cells.",[10],{"type":11,"name":12,"description":13,"armGroupLabels":7,"otherNames":14},"DRUG","Tempol","Tempol will be given as an adjunct to chemotherapy.",[15],"MBM-0-1 MBM-02",[17],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"Benji Crane","CONTACT","6264376506","bjcrane@matrixbiomed.com",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":7},"UCHealth University of Colorado Cancer Center - Anschutz Medical Campus","AVAILABLE","Aurora","Colorado","80045","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-104.83192,39.72943,{"lat":35,"lon":34},{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100477051",false,"NCT05491928","Treatment of Metastatic Cancer in Terminally Diagnosed Patients","Inclusion Criteria:\n\n* metastatic terminally diagnosed cancer\n\nExclusion Criteria:\n\n\\-","ALL","EXPANDED_ACCESS","The objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. Tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.",[48],"Metastatic Cancer","2022-08-31",{"date":51,"type":52},"2022-09-01","ACTUAL",{"name":5,"class":6},1]